BioSpace News Archive

United Therapeutics Corporation announced that it has launched commercial sales of the innovative Remunity® Pump for Remodulin® for patients with pulmonary arterial hypertension.

RepliCel Life Sciences Inc., a company developing next-generation technologies in aesthetics and orthopedics, announced it has closed the first tranche of the investment by MainPointe Pharmaceuticals as outlined in the share purchase agreement signed earlier this year by the parties.

Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced the successful completion of dosing of the first patient cohort (n=3) in a Phase I dose escalation study, evaluating the safety and efficacy of Tessa’s TT11X

Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company focused on accelerating new, promising targeted therapies for children and adults with cancer, today announced a $130 million Series B financing from leading life sciences investors

TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that it will host a virtual Investor Day on February 23, 2021, beginning at 11:00am Eastern Time.

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that management will participate in a virtual fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 8:00 a.m. ET.

XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that it has closed the over-subscribed private placement, initially announced on January 7, 2021, for total gross proceeds of $6.1 million (the “ Offering ”). In connection with the Offering, the Company issued an aggregate of 24,486,

Catalent Announces Launch of Private Offering of $475 Million of Senior Unsecured Notes Due 202 9

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy, announced today that members of the Avadel management team will participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference,

Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today provided several updates on its lead clinical-stage program, YTX-7739, in development for the treatment of Parkinson’s Disease.